Standard BioTools completes sale of SomaScan business to Illumina for ~$363.7M net cash

STANDARD BIOTOOLS INC.

Net cash proceeds of ~$363.7M from sale of SomaLogic and Sengenics entities to Illumina.
Potential earnout payments up to $75M based on 2025/2026 revenue milestones.
Pro forma cash and equivalents of $478.3M as of Sep 30, 2025; gain on sale of $161.9M.
Company retains mass cytometry and microfluidics businesses; no longer party to Collaboration Agreement.
Transaction expenses of $18.4M incurred; $14.8M paid at closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.